Skip to main content

Table 1 Baseline characteristics in intent-to-treatment population

From: CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial

 CEOP/IVE/GDP (N = 51)CEOP (N = 51)
Age (years; median IQR)56 (46.0–64.0)60 (52.0–65.0)
 ≤ 60 years33 (65%)28 (55%)
 > 60 years18 (35%)23 (45%)
Gender
 Male34 (67%)32 (63%)
 Female17 (33%)19 (37%)
Ann Arbor Stage
 I–II10 (20%)9 (18%)
 III–IV41 (80%)42 (82%)
B symptoms
 Absent26 (51%)23 (45%)
 Present25 (49%)28 (55%)
Performance status
 0–146 (90%)42 (82%)
 25 (10%)9 (18%)
Serum LDH
 Normal25 (49%)28 (55%)
 Elevated26 (51%)23 (45%)
EBV-DNA
 Undetectable35/45 (78%)30/42 (71%)
 Detectable10/45 (22%)12/42 (29%)
Extra-nodal involvement
 0–134 (67%)30 (59%)
 ≥ 217 (33%)21 (41%)
Extra-nodal site
 Skin4 (8%)5 (10%)
 Gastrointestinal tract5 (10%)7 (14%)
 Liver4 (8%)2 (4%)
 Spleen14 (27%)14 (27%)
 Lung2 (4%)3 (6%)
 Bone marrow15 (30%)21 (41%)
 Bone5 (10%)8 (16%)
 Breast01 (2%)
IPI
 0–114 (27%)16 (31%)
 2–330 (59%)26 (51%)
 4–57 (14%)9 (18%)
  1. Data are median (IQR), n (%), or n/N (%). CEOP cyclophosphamide, epirubicin, vincristine, and prednisone, IVE ifosmide, epirubicin, and etoposide, GDP gemcitabine, cisplatin, and dexamethasone, LDH lactate dehydrogenase, IPI International Prognostic Index